Selected research
Market Structure
Global Urinary Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Urinary Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Urinary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Urinary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Urinary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Urinary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Urinary Drugs include Sanofi S.A., Pfizer Inc., GlaxosmithKline Plc., Bayer AG, Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Company Limited, Astellas Pharma Inc. and Allergan Plc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Urinary Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Urinary Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Urinary Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Urinary Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Urinary Drugs Segment by Company
Sanofi S.A.
Pfizer Inc.
GlaxosmithKline Plc.
Bayer AG
Otsuka Pharmaceutical Co., Ltd.
Daiichi Sankyo Company Limited
Astellas Pharma Inc.
Allergan Plc.
Urinary Drugs Segment by Type
Oral
Injectables
Urinary Drugs Segment by Application
Clinic
Hospital
Home Care
Urinary Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urinary Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Urinary Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urinary Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Urinary Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Urinary Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Urinary Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Urinary Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injectables
Applications
- Clinic
- Hospital
- Home Care
Companies covered
- Sanofi S.A.
- Pfizer Inc.
- GlaxosmithKline Plc.
- Bayer AG
- Otsuka Pharmaceutical Co., Ltd.
- Daiichi Sankyo Company Limited
- Astellas Pharma Inc.
- Allergan Plc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Urinary Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Urinary Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Urinary Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Urinary Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Urinary Drugs Market Dynamics
- 2.1 Urinary Drugs Industry Trends
- 2.2 Urinary Drugs Industry Drivers
- 2.3 Urinary Drugs Industry Opportunities and Challenges
- 2.4 Urinary Drugs Industry Restraints
3 Urinary Drugs Market by Manufacturers
- 3.1 Global Urinary Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Urinary Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Urinary Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Urinary Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Urinary Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Urinary Drugs Manufacturers, Product Type & Application
- 3.7 Global Urinary Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Urinary Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Urinary Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Urinary Drugs Tier 1, Tier 2, and Tier 3
4 Urinary Drugs Market by Type
- 4.1 Urinary Drugs Type Introduction
- 4.1.1 Oral
- 4.1.2 Injectables
- 4.2 Global Urinary Drugs Sales by Type
- 4.2.1 Global Urinary Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Urinary Drugs Sales by Type (2021-2032)
- 4.2.3 Global Urinary Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Urinary Drugs Revenue by Type
- 4.3.1 Global Urinary Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Urinary Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Urinary Drugs Revenue Market Share by Type (2021-2032)
5 Urinary Drugs Market by Application
- 5.1 Urinary Drugs Application Introduction
- 5.1.1 Clinic
- 5.1.2 Hospital
- 5.1.3 Home Care
- 5.2 Global Urinary Drugs Sales by Application
- 5.2.1 Global Urinary Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Urinary Drugs Sales by Application (2021-2032)
- 5.2.3 Global Urinary Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Urinary Drugs Revenue by Application
- 5.3.1 Global Urinary Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Urinary Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Urinary Drugs Revenue Market Share by Application (2021-2032)
6 Global Urinary Drugs Sales by Region
- 6.1 Global Urinary Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Urinary Drugs Sales by Region (2021-2032)
- 6.2.1 Global Urinary Drugs Sales by Region (2021-2026)
- 6.2.2 Global Urinary Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Urinary Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Urinary Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Urinary Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Urinary Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Urinary Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Urinary Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Urinary Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Urinary Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Urinary Drugs Revenue by Region
- 7.1 Global Urinary Drugs Revenue by Region
- 7.1.1 Global Urinary Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Urinary Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Urinary Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Urinary Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Urinary Drugs Revenue (2021-2032)
- 7.2.2 North America Urinary Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Urinary Drugs Revenue (2021-2032)
- 7.3.2 Europe Urinary Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Urinary Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Urinary Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Urinary Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Urinary Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Sanofi S.A.
- 8.1.1 Sanofi S.A. Company Information
- 8.1.2 Sanofi S.A. Business Overview
- 8.1.3 Sanofi S.A. Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Sanofi S.A. Urinary Drugs Product Portfolio
- 8.1.5 Sanofi S.A. Recent Developments
- 8.2 Pfizer Inc.
- 8.2.1 Pfizer Inc. Company Information
- 8.2.2 Pfizer Inc. Business Overview
- 8.2.3 Pfizer Inc. Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Pfizer Inc. Urinary Drugs Product Portfolio
- 8.2.5 Pfizer Inc. Recent Developments
- 8.3 GlaxosmithKline Plc.
- 8.3.1 GlaxosmithKline Plc. Company Information
- 8.3.2 GlaxosmithKline Plc. Business Overview
- 8.3.3 GlaxosmithKline Plc. Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 GlaxosmithKline Plc. Urinary Drugs Product Portfolio
- 8.3.5 GlaxosmithKline Plc. Recent Developments
- 8.4 Bayer AG
- 8.4.1 Bayer AG Company Information
- 8.4.2 Bayer AG Business Overview
- 8.4.3 Bayer AG Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Bayer AG Urinary Drugs Product Portfolio
- 8.4.5 Bayer AG Recent Developments
- 8.5 Otsuka Pharmaceutical Co., Ltd.
- 8.5.1 Otsuka Pharmaceutical Co., Ltd. Company Information
- 8.5.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
- 8.5.3 Otsuka Pharmaceutical Co., Ltd. Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Otsuka Pharmaceutical Co., Ltd. Urinary Drugs Product Portfolio
- 8.5.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments
- 8.6 Daiichi Sankyo Company Limited
- 8.6.1 Daiichi Sankyo Company Limited Company Information
- 8.6.2 Daiichi Sankyo Company Limited Business Overview
- 8.6.3 Daiichi Sankyo Company Limited Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Daiichi Sankyo Company Limited Urinary Drugs Product Portfolio
- 8.6.5 Daiichi Sankyo Company Limited Recent Developments
- 8.7 Astellas Pharma Inc.
- 8.7.1 Astellas Pharma Inc. Company Information
- 8.7.2 Astellas Pharma Inc. Business Overview
- 8.7.3 Astellas Pharma Inc. Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Astellas Pharma Inc. Urinary Drugs Product Portfolio
- 8.7.5 Astellas Pharma Inc. Recent Developments
- 8.8 Allergan Plc.
- 8.8.1 Allergan Plc. Company Information
- 8.8.2 Allergan Plc. Business Overview
- 8.8.3 Allergan Plc. Urinary Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Allergan Plc. Urinary Drugs Product Portfolio
- 8.8.5 Allergan Plc. Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Urinary Drugs Value Chain Analysis
- 9.1.1 Urinary Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Urinary Drugs Production Mode & Process
- 9.2 Urinary Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Urinary Drugs Distributors
- 9.2.3 Urinary Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst